May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 08, 2020
Lilly Receives U.S. FDA Approval for Retevmo(TM) (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
May 08, 2020
FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion
Mar 04, 2020
$770M Thyroid Cancer Drugs Market Insights, 2015-2030
Jan 29, 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Dec 30, 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Sep 29, 2019
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
Sep 09, 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Aug 13, 2019
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
Jul 02, 2019
The anaplastic thyroid cancer drugs market at a CAGR of more than 4% during the forecast period
Jun 03, 2019
Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
Mar 21, 2019
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)
Jul 20, 2018
Taiwan Unveils Latest Medical Inventions to Advance Science During FIME in Orlando
Jul 18, 2018
Thyroid Gland Disorder Treatment Market Worth $2,771 Million by 2025 | CAGR 3.8% - Allied Market Research
Jul 10, 2018
New Taiwan Technology Gives Doctors Superhuman Powers Improving Patient Care
Apr 15, 2018
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
Apr 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
Feb 13, 2018
Cabozantinib shows significant activity in the first line for differentiated thyroid cancer
Jan 25, 2018
American Cancer Society® Published Performance Results Of ThyroSeq® V3
Jan 12, 2018
Testicular Cancer Forecast in 24 Major Markets 2018-2028